Skip to main content

Table 4 The effect on the survival status of currently used markers compared to BTG2 expression

From: Up-regulation of cell cycle arrest protein BTG2 correlates with increased overall survival in breast cancer, as detected by immunohistochemistry using tissue microarray

A Odds Ratio 95%CI P-value C-index
Age 1.058 1.031; 1.087 < 0.0001* 0.711
BTG2 both 0.338 0.336; 0.339 < 0.0001* 0.768
BTG2 cytoplasm 0.699 0.697; 0.700 < 0.0001* 0.768
BTG2 membrane 0.980 0.977; 0.983 < 0.0001* 0.768
HER2 3.331 3.248; 3.416 < 0.0001* 0.768
Ki67 2.441 1.202; 4.956 0.013* 0.758
B Odds Ratio 95%CI P-value C-index
Age 1.058 1.032; 1.085 < 0.0001* 0.696
HER2 2.668 2.640; 2.696 < 0.0001* 0.761
Histological grade 2 0.954 0.294; 3.094 0.938 0.770
Histological grade 3 1.463 0.432; 4.949 0.539 0.770
Hormone receptor status 0.567 0.248; 1.296 0.179 0.767
Nodal Status 1.673 0.823; 3.398 0.154 0.768
Tumour size 1.569 0.739; 3.330 0.240 0.765
  1. A Cox-regression multivariate analysis was performed to test the effect on survival status of the markers used in current clinical praxis and the changes in the model predictive power induced by the removal of a single marker. The predictive power of the full new model as measured by the C-index is 0.781 (A). The C-index for the old model is 0.772 (B), and the model with only the statistically significant variables in the old model has a predictive power of 0.739.